Editas Medicine (NASDAQ: EDIT)
Editas Medicine Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Editas Medicine Company Info
Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.
News & Analysis
Why Editas Medicine Stock Was Skyrocketing This Week
The company's CEO made quite the encouraging statement regarding its immediate future.
Can This Beaten-Down Stock Bounce Back?
This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success.
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
2 Beaten-Down Stocks to Avoid
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
Editas Medicine: A Cautionary Tale for Investors
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
The company has great potential if and when it enters the commercial stage.
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The company now has a chance to get its lead program out the door a bit sooner.
Valuation
Podcast Episodes
Earnings Transcripts
Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript
EDIT earnings call for the period ending September 30, 2021.
Editas Medicine, inc (EDIT) Q2 2021 Earnings Call Transcript
EDIT earnings call for the period ending June 30, 2021.
Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript
EDIT earnings call for the period ending March 31, 2021.
Editas Medicine, Inc. (EDIT) Q4 2020 Earnings Call Transcript
EDIT earnings call for the period ending .
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.